0.7196  -0.115 (-13.77%)		04-17 16:00
Open: 0.76 High: 0.76 Volume: 1,626,091		Pre. Close: 0.8345 Low: 0.6723 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	1.33	1-year :	1.74
Resists	First :	1.14	Second :	1.49
Pivot price	1.05
Supports	First :	0.58	Second :	0.48
MAs	MA(5) :	0.9	MA(20) :	0.96
	MA(100) :	2.16	MA(250) :	23.43
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	14.2	D(3) :	25.4
RSI	RSI(14): 39.9
52-week	High :	52.4	Low :	0.58

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CMND ] has closed above bottom band by 12.6%. Bollinger Bands are 77% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.76 - 0.76	0.76 - 0.77
Low:	0.66 - 0.67	0.67 - 0.67
Close:	0.71 - 0.72	0.72 - 0.73

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Thu, 16 Apr 2026
symbol__ Stock Quote Price and Forecast - CNN

Thu, 16 Apr 2026
CMND Technical Analysis | Trend, Signals & Chart Patterns | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill

Wed, 15 Apr 2026
Clearmind shares surge as CMND-100 achieves primary endpoint in clinical trial - MSN

Wed, 15 Apr 2026
Positive DSMB backs Clearmind (Nasdaq: CMND) CMND-100 AUD trial - Stock Titan

Wed, 15 Apr 2026
Alcohol disorder drug advances after no serious adverse events - Stock Titan

Wed, 15 Apr 2026
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	2 (M)
Held by Insiders	4.4 (%)
Held by Institutions	0.4 (%)
Shares Short	64 (K)
Shares Short P.Month	133 (K)

EPS	-24.13
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.48
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-55.3 %
Return on Equity (ttm)	-119.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.75
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-0.03
PEG Ratio	0
Price to Book value	0.13
Price to Sales	0
Price to Cash Flow	-0.28

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.